Mantle Cell Lymphoma News

News

Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features

02/14/2024

Grace Taylor , MS, MA;

A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...

A recent study investigated...

02/14/2024

Journal of Clinical Pathways

Conference Coverage

Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma

12/10/2022

Katie Herman ;

Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...

Mitchell R Smith, MD, and...

12/10/2022

Journal of Clinical Pathways

News

Study Indicates Late Effects in Mantle Cell Lymphoma Treatment With or Without Transplantation Have Minimal Impact

09/12/2022

Yvette C. Terrie , BS Pharm, RPh;

Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...

Results from a recent study...

09/12/2022

Journal of Clinical Pathways

News

Exploring Radiation Therapy for Orbital Involvement in Patients with Mantle Cell Lymphoma

09/12/2022

Yvette C. Terrie , BS Pharm, RPh;

Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.

Mantle cell lymphoma with optic...

09/12/2022

Journal of Clinical Pathways

News

Exploring PD-1/PD-L1 Expression in Mantle Cell Lymphoma and its Significance as an Immune Check Point Inhibitor

08/26/2022

Yvette C. Terrie , BS Pharm, RPh;

Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.

Findings from a recent study...

08/26/2022

Journal of Clinical Pathways

News

Autologous Stem-Cell Transplant Underutilized Among Patients With Mantle Cell Lymphoma in US Community Settings

08/16/2022

Yvette C. Terrie , BS Pharm, RPh;

Study findings reveal that among a large cohort of patients treated primarily in the US community setting, one in four patients received cytarabine or autologous stem-cell transplant consolidation, indicating the need to develop treatments...

Study findings reveal that among...

08/16/2022

Journal of Clinical Pathways

News

Survey Explores Prescriber Perceptions and Preferences Regarding First Line Therapy for MCL

07/27/2022

Ellen Kurek ;

A survey evaluated first-line therapy preferences for treatment-naïve patients with MCL in routine practice and perceptions surrounding benefits and risks of the lenalidomide plus rituximab plus venetoclax triplet regimen.

A survey evaluated first-line...

07/27/2022

Journal of Clinical Pathways

News

Evaluating Attrition Rates and Treatment Outcomes Among Patients With MCL

07/14/2022

Ellen Kurek ;

Findings from a recent real-world analysis on patients with mantle cell lymphoma revealed high attrition rates, as well as a need for more effective treatment options for those in earlier lines of therapy.

Findings from a recent...

07/14/2022

Journal of Clinical Pathways

News

Real-World Treatment Patterns Among Patients With Mantle Cell Lymphoma

05/27/2022

Marta Rybczynski ;

For the treatment of MCL, a recent study found that bendamustine and rituximab was the most used frontline regimen, while BTK inhibitors were the most used agents in later lines of therapy.

For the treatment of MCL, a...

05/27/2022

Journal of Clinical Pathways

News

Cost-Effectiveness of Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed or Refractory MCL

04/27/2022

Ellen Kurek ;

Second-generation BTKis acalabrutinib and zanubrutinib may provide additional progression-free survival among patients with relapsed or refractory mantle cell lymphoma, compared with first-generation BTKi ibrutinib, according to an early...

Second-generation BTKis...

04/27/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Mantle Cell Lymphoma News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products